Original Contributions |
From the Departments of Medicine (R.A.M., A.H.M., J.F., J.K.S., C.G., K.R.F.) and Dermatology (W.M.H., T.S., Y.U.), University of California, San Francisco, and Metabolism Section, Medical and Dermatology Services, Veterans Affairs Medical Center, San Francisco, Calif.
Correspondence to Kenneth R. Feingold, MD, Metabolism Section (111F), Veterans Affairs Medical Center, 4150 Clement St, San Francisco, CA 94121. E-mail kfngld{at}itsa.ucsf.edu
AbstractAlterations in triglyceride and cholesterol
metabolism often accompany inflammatory diseases and
infections. We studied the effects of endotoxin
(lipopolysaccharide [LPS]) and cytokines on hepatic
sphingolipid synthesis, activity of serine palmitoyltransferase (SPT),
the first and rate-limiting enzyme in sphingolipid synthesis, and
lipoprotein sphingolipid content in Syrian hamsters. Administration of
LPS induced a 2-fold increase in hepatic SPT activity. The increase in
activity first occurred at 16 hours, peaked at 24 hours, and was
sustained for at least 48 hours. Low doses of LPS produced maximal
increases in SPT activity, with half-maximal effect seen at
0.3 µg
LPS/100 g body weight. LPS increased hepatic SPT mRNA levels 2-fold,
suggesting that the increase in SPT activity was due to an increase in
SPT mRNA. LPS treatment also produced 75% and 2.5-fold increases in
hepatic sphingomyelin and ceramide synthesis, respectively. Many of the
metabolic effects of LPS are mediated by cytokines.
Interleukin 1 (IL-1), but not tumor necrosis factor, increased both SPT
activity and mRNA levels in the liver of intact animals, whereas both
IL-1 and tumor necrosis factor increased SPT mRNA levels in HepG2
cells. IL-1 produced a 3-fold increase in SPT mRNA in HepG2 cells, and
the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of
sphingolipids into the medium. Analysis of serum lipoprotein
fractions demonstrated that very low density lipoprotein, intermediate
density lipoprotein, and low density lipoprotein isolated from animals
treated with LPS contained significantly higher amounts of ceramide,
glucosylceramide, and sphingomyelin. Taken together, these results
indicate that LPS and cytokines stimulate hepatic sphingolipid
synthesis, which results in an altered structure of circulating
lipoproteins and may promote atherogenesis.
Key Words: acute-phase response tumor necrosis factor interleukin-1 serine palmitoyltransferase atherogenesis
This article has been cited by other articles:
![]() |
N. Bartolome, B. Arteta, M. J. Martinez, Y. Chico, and B. Ochoa Kupffer cell products and interleukin 1? directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes Innate Immunity, August 1, 2008; 14(4): 255 - 266. [Abstract] [PDF] |
||||
![]() |
J. Shen, D. K. Arnett, P. Perez-Martinez, L. D. Parnell, C.-Q. Lai, J. M. Peacock, J. E. Hixson, M. Y. Tsai, R. J. Straka, P. N. Hopkins, et al. The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN study,boxs J. Lipid Res., August 1, 2008; 49(8): 1839 - 1845. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Popa, F. H J van den Hoogen, T. R D J Radstake, M. G Netea, A. E Eijsbouts, M. d. Heijer, J. W M van der Meer, P. L C M van Riel, A. F H Stalenhoef, and P. Barrera Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(11): 1503 - 1507. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Popa, M. G. Netea, P. L. C. M. van Riel, J. W. M. van der Meer, and A. F. H. Stalenhoef The role of TNF-{alpha} in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk J. Lipid Res., April 1, 2007; 48(4): 751 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Singh and P. V. Subbaiah Modulation of the activity and arachidonic acid selectivity of group X secretory phospholipase A2 by sphingolipids J. Lipid Res., March 1, 2007; 48(3): 683 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. He, H. Suzuki, N. Sharma, and R. P. Sharma Ceramide Synthase Inhibition by Fumonisin B1 Treatment Activates Sphingolipid-Metabolizing Systems in Mouse Liver Toxicol. Sci., December 1, 2006; 94(2): 388 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
V E MacRae, T Burdon, S F Ahmed, and C Farquharson Ceramide inhibition of chondrocyte proliferation and bone growth is IGF-I independent. J. Endocrinol., November 1, 2006; 191(2): 369 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Aspichueta, B. Perez-Agote, S. Perez, B. Ochoa, and O. Fresnedo Impaired response of VLDL lipid and apoB secretion to endotoxin in the fasted rat liver Innate Immunity, June 1, 2006; 12(3): 181 - 191. [Abstract] [PDF] |
||||
![]() |
V. E. MacRae, C. Farquharson, and S. F. Ahmed The pathophysiology of the growth plate in juvenile idiopathic arthritis Rheumatology, January 1, 2006; 45(1): 11 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Strle, S. R. Broussard, R. H. McCusker, W.-H. Shen, R. W. Johnson, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokine Impairment of Insulin-Like Growth Factor I-Induced Protein Synthesis in Skeletal Muscle Myoblasts Requires Ceramide Endocrinology, October 1, 2004; 145(10): 4592 - 4602. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-y. Morita, M. Kawabe, A. Sakurai, K. Okuhira, A. Vertut-Doi, M. Nakano, and T. Handa Ceramide in Lipid Particles Enhances Heparan Sulfate Proteoglycan and Low Density Lipoprotein Receptor-related Protein-mediated Uptake by Macrophages J. Biol. Chem., June 4, 2004; 279(23): 24355 - 24361. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Malagarie-Cazenave, B. Segui, S. Leveque, V. Garcia, S. Carpentier, M.-F. Altie, A. Brouchet, V. Gouaze, N. Andrieu-Abadie, Y. Barreira, et al. Role of FAN in Tumor Necrosis Factor-{alpha} and Lipopolysaccharide-induced Interleukin-6 Secretion and Lethality in D-Galactosamine-sensitized Mice J. Biol. Chem., April 30, 2004; 279(18): 18648 - 18655. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Boyanovsky, A. Karakashian, K. King, N. Giltiay, and M. Nikolova-Karakashian Uptake and Metabolism of Low Density Lipoproteins with Elevated Ceramide Content by Human Microvascular Endothelial Cells: IMPLICATIONS FOR THE REGULATION OF APOPTOSIS J. Biol. Chem., July 11, 2003; 278(29): 26992 - 26999. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Carton, D. J. Uhlinger, A. D. Batheja, C. Derian, G. Ho, D. Argenteri, and M. R. D'Andrea Enhanced Serine Palmitoyltransferase Expression in Proliferating Fibroblasts, Transformed Cell Lines, and Human Tumors J. Histochem. Cytochem., June 1, 2003; 51(6): 715 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Yoo and S. Desiderio Innate and acquired immunity intersect in a global view of the acute-phase response PNAS, February 4, 2003; 100(3): 1157 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Uchida, S. Murata, M. Schmuth, M. J. Behne, J. D. Lee, S. Ichikawa, P. M. Elias, Y. Hirabayashi, and W. M. Holleran Glucosylceramide synthesis and synthase expression protect against ceramide-induced stress J. Lipid Res., August 1, 2002; 43(8): 1293 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Merrill Jr. De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, Pathway J. Biol. Chem., July 12, 2002; 277(29): 25843 - 25846. [Full Text] [PDF] |
||||
![]() |
R. A. Memon, W. M. Holleran, Y. Uchida, A. H. Moser, C. Grunfeld, and K. R. Feingold Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin J. Lipid Res., March 1, 2001; 42(3): 452 - 459. [Abstract] [Full Text] |
||||
![]() |
S. Barlage, D. Fröhlich, A. Böttcher, M. Jauhiainen, H. P. Müller, F. Noetzel, G. Rothe, C. Schütt, R. P. Linke, K. J. Lackner, et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response J. Lipid Res., February 1, 2001; 42(2): 281 - 290. [Abstract] [Full Text] |
||||
![]() |
R. A. Memon, I. Staprans, M. Noor, W. M. Holleran, Y. Uchida, A. H. Moser, K. R. Feingold, and C. Grunfeld Infection and Inflammation Induce LDL Oxidation In Vivo Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1536 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Memon, W. M. Holleran, Y. Uchida, A. H. Moser, S. Ichikawa, Y. Hirabayashi, C. Grunfeld, and K. R. Feingold Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Response J. Biol. Chem., July 9, 1999; 274(28): 19707 - 19713. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Memon, J. Fuller, A. H. Moser, K. R. Feingold, and C. Grunfeld In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1999; 277(1): R94 - R103. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Van Lenten, A. C. Wagner, M. Navab, and A. M. Fogelman Oxidized Phospholipids Induce Changes in Hepatic Paraoxonase and ApoJ but Not Monocyte Chemoattractant Protein-1 via Interleukin-6 J. Biol. Chem., January 12, 2001; 276(3): 1923 - 1929. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |